Early Results For Therapyx/Intravacc's Vaccine May Herald Progress In Gonorrhea Prevention

SBIR Award Received From The US NIAID

Therapyx and Intravacc are optimizing a candidate gonorrhea vaccine following promising results in primates and the granting of a three-year SBIR award by the US NIAID.

Gonorrhea
Neisseria gonorrhoeae • Source: Shutterstock

Gonorrhea has been intractable to the development of a vaccine, but the US biotech TherapyX Inc. working with the Netherlands R&D organization Intravacc have induced immune responses in primates with their mucosal immunization approach, NGoXIM, and Therapyx has just received a $2.8m US government grant to support the research.

Neisseria gonorrhoeae infections are usually treated with penicillin or other antibiotics, but with resistant strains becoming more common, and most individuals not developing protective immunity from earlier

More from Deals

More from Business

Strong Showing For Bayer’s Pharma Business In Uncertain Times

 
• By 

As CEO Anderson backs high prices for innovative drugs in Europe

Stock Watch: Stock Watch: Lilly And Novo Duke Out Q1

 
• By 

Novo Nordisk enjoyed a surprise GLP-1 agonist contracting win in the first quarter of 2025. This provided a welcome boost to its stock after it had spent the previous quarter on the back foot against rival Lilly.

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By 

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.